There are a number of obvious reasons why Life Technologies is not doing well.
The sequencing in this study was done with the SOLID system made by Life Technologies.
FORBES: DNA Sequencing: Is Science Fiction Becoming Medical Fact?
The principal competitor machine made by Life Technologies has temperature uniformity to within 0.5 degrees Celsius.
On January 10, Life Technologies and Illumina both announced plans for faster, same-day DNA sequencers.
FORBES: Is This The End Of The Half Million-Dollar DNA Sequencer?
Two of them are Life Technologies Corp. (nasdaq: LIFE) and Illumina, Inc. (nasdaq: ILMN).
"It's difficult for another company to come into this market, " says Life Technologies Chief Executive Gregory Lucier.
"The mobile device is becoming much more than email and calendar, " said Joe Beery, Life Technologies' chief information officer.
Life Technologies (LIFE) reports its fourth quarter earnings on Monday, February 4, 2013.
Numerous companies inlcuding Illumina and Life Technologies sell gene decoding machines that are getting faster and cheaper all the time.
FORBES: Do-It-Yourself Gene Testing Threatens Myriad's Monopoly
The majority of analysts think investors should stand pat on Life Technologies, with nine of 16 analysts rating it hold.
To be sure, there are other diagnostics makers like Life Technologies and Illumina, that have been hot growth stocks.
FORBES: Danaher Acquires Beckman Coulter: Are Health Care Companies Waving The White Flag?
Life Technologies is a much more manageable 30 on a more diverse revenue base that includes lots of other lab reagents.
Illumina rival Life Technologies is betting heavily on a smaller, less expensive to buy machine that might be good for smaller projects.
FORBES: Sequencing A Child's DNA -- And Convincing An Insurance Company To Pay
Analyst sentiment about Life Technologies has waned during the last three months.
Investors are betting that, given the headway being made in DNA sequencing, it is undervalued compared to larger rivals like Illumina and Life Technologies.
Rival Life Technologies and upstart Complete Genomics are down 20%, too.
FORBES: The Future Is Now: 23andMe Now Offers All Your Genes For $999
Certainly, from a business perspective, this presents problems for Life Technologies.
The majority of analysts (58.8%) rate Life Technologies as a buy.
Life Technologies, a life science tools company based in Carlsbad, Calif.
Now, he thinks he has found the perfect tool: a new DNA sequencing device called the Ion Torrent Personal Genome Machine, made by Life Technologies of Carlsbad, Calif.
Is the effort to treat experiments in genetics just like clinical trials hurting our ability to use the new technology coming from companies like Illumina, Life Technologies, and Complete Genomics?
Analysts are expecting Life Technologies to come in with earnings of 89 cents per share, 5.3% less than a year ago when it reported earnings of 94 cents per share.
Vendors that have deployed hundreds or thousands of iPads installed with marketing and CRM apps to the field include Medtronic, Abbott Laboratories, Boston Scientific, Otsuka, Zimmer and Life Technologies .
FORBES: Connecting marketers to the Forbes audience. What is this?
One challenge for all the new sequencing companies will be that Illumina and Life Technologies, the market leaders, have been able to increase the speed of their machines very quickly without fundamental changes in technology.
The app, meant to be used on the iPads, takes sales data and arranges it in interactive graphs, making it easier for Life Technologies' sales team to make sense of mountains of sales and customer data while on the road.
Quick recap: his new device, the Ion Torrent Personal Genome Machine, is a less expensive machine that provides more limited DNA information than can be had from current devices sold by Illumina of San Diego and Life Technologies of Carlsbad, Calif.
Just today, Life Technologies announced that it is expects to increase the speed of its smaller, cheaper DNA 10-fold in just six months, illustrating how a war between makers of DNA-sequencing gear is driving the science behind this type of research.
Life Technologies, formed by the merger last year of life science tools companies Applied Biosystems and Invitrogen, has an estimated 65% of the market for PCR machines used for research and has licensed its technology to 12 other companies making the machines.
应用推荐